Evidence map›Paper›PMID 42277206›Full record

ArticleActa pharmacologica Sinica2026

Paclitaxel prodrug loaded high-density lipoprotein nanoparticles for chemoimmunotherapy of triple-negative breast cancer.

Lin-Yang Jiang, Bin-Yu Zhu, Ling-Li Zhou, Dong Deng, Xiao-Yu Zhang, Jia-Meng Chen, Pei-Wen Jiang, Guan-Ru Wang, Qing-Min Yang, Ming-Hui Zhang and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Acta pharmacologica Sinica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Lin-Yang JiangState Key Laboratory of Drug Research & Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
Bin-Yu ZhuState Key Laboratory of Drug Research & Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
Ling-Li ZhouSchool of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
Dong DengSchool of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
Xiao-Yu ZhangSchool of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
Jia-Meng ChenState Key Laboratory of Drug Research & Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
Pei-Wen JiangState Key Laboratory of Drug Research & Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
Guan-Ru WangState Key Laboratory of Drug Research & Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
Qing-Min YangQilu Pharmaceutical Co. Ltd., Jinan, 250100, China.
Ming-Hui ZhangQilu Pharmaceutical Co. Ltd., Jinan, 250100, China.
Yan-Qiang ShanQilu Pharmaceutical (Hainan) Co. Ltd., Haikou, 570314, China.
Han-Zhi LiHongliang (Shanghai) Biopharmaceutical Technology Co. Ltd, Shanghai, 200131, China.
Ya-Ping LiState Key Laboratory of Drug Research & Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China. ypli@simm.ac.cn.
Ying CaiState Key Laboratory of Drug Research & Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China. s19-caiying@simm.ac.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Insufficient tumor-specific immunogenicity and cytotoxic T lymphocytes infiltration limit the therapeutic efficacy of combined chemotherapy and immune checkpoint blockade for triple-negative breast cancer (TNBC). To address this limitation, we developed a paclitaxel prodrug-loaded synthetic high-density lipoprotein nanoparticle (P-sHDL) that both targets tumors and induces immunogenic cell death (ICD) to potentiate immune checkpoint blockade. Leveraging scavenger receptor class B type 1-mediated uptake, P-sHDL efficiently accumulated at tumor sites and triggered ICD in tumor cells, thereby enhancing antitumor immunogenicity. Building on this immunogenicity enhancement, P-sHDL was combined with an anti-programmed death-ligand 1 antibody (αPD-L1) to enhance intratumoral CD8

Indexed as

chemoimmunotherapyimmunogenic cell deathpaclitaxelsynthetic high-density lipoproteintriple-negative breast cancer

Identifiers

PMID42277206

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.